Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Revision of Appendix 3B lodged 16 September 2015 New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity	
PARA	AGON CARE LIMITED	
ABN 76 06	4 551 426	
We (t	the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	8,823,338
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares to rank equally in all respects with existing ordinary shares.

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Fully paid ordinary shares ranking equally in all respects with existing ordinary shares. The new shares are subject to an Appendix 9A Restriction Agreement with an escrow period of twelve months from 1 March 2018.

5 Issue price or consideration

\$0.7250 per fully paid ordinary share

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Part consideration for the acquisition of the Surgical Specialties business as announced on 28 February 2018.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

22 November 2017

6b The date the security holder resolution under rule 7.1A was passed

issued 29,447,189 proval Refer Annexure 1 Part 1

6c Number of *securities issued without security holder approval under rule 7.1

+ See chapter 19 for defined terms.

16,621,461 new Shares pursuant to the 6d Number of *securities issued with security holder approval Placement under rule 7.1A Refer Annexure 1 Part 2 Nil 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 26,168,501 shares issued under the DRP and 6f Number of *securities issued under an exception in rule 7.2 institutional entitlement offer announced on 8 February 2018. Refer Annexure 1 Part 1 Yes. Issue price (\$0.725 per share) is 93% of 6g If +securities issued under rule 7.1A, was issue price at least 75% the 15 day VWAP calculated for the trading of 15 day VWAP as calculated days for PGC up to and including 6/02/2018 under rule 7.1A.3? Include the (the last trading day prior to the issue price +issue date and both values. being fixed), being \$0.783 per share. Include the source of the VWAP Source: Weblink Pty Ltd (data provider) calculation. https://www.weblink.com.au N/A 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements** Calculate the entity's remaining 6i 4,418,868 Shares remaining issue capacity issue capacity under rule 7.1 and under Rule 7.1 after the Placement rule 7.1A - complete Annexure 1

and release to ASX Market

Announcements

Nil remaining issue capacity under Rule

7.1A after the Placement

Refer Annexure 1

⁺ See chapter 19 for defined terms.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

2 March 2018		

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

Number	⁺ Class
237,360,435	Fully paid ordinary shares
Approximately 272 million Shares (after Retail Entitlement Offer and Underwriters' shortfall settled on 5 March 2018)	Fully paid ordinary shares

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

	Number	⁺ Class
	N/A	N/A
l		

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No change to dividend policy.

Part 2 - Pro rata issue

The new shares are not issued pursuant to a Pro Rate Issue and questions 11 to 35 not applicable.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of *securities (tick one)

⁺ See chapter 19 for defined terms.

(a)	⁺ Securities described in Part 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

The new shares do not form a new class of securities and questions 35 to 37 not applicable

Entities that have ticked box 34(b)

Box 34(b) not ticked and questions 38 to 42 not applicable

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

⁺ See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: John Osborne

Company secretary

Date: 2 March 2018

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	164,597,364	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an	04-Apr-17 - issue of shares under Dividend Reinvestment Plan (DRP) - 420,645	
 exception in rule 7.2 Number of fully paid +ordinary securities 	06-Oct-17 - issue of shares under DRP - 670,677	
issued in that 12 month period with shareholder approval	14-Aug-17 - Part consideration for acquisition of Medtek business and earn out	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	consideration in lieu of cash consideration to vendor of Western Biomedical business - 525,920	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	Entitlement Offer which will be allotted by 5 March 2018 (ASX waiver of listing rule 7.1) - 59,559,109	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil	
"A"	225,773,715	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]		
Multiply "A" by 0.15	33,866,057		
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Anaequip part consideration – 550,898 Surgical Specialties part consideration -		
 Under an exception in rule 7.2 	8,823,338 Institutional placement - 20,072,953		
Under rule 7.1A	matitutional placement - 20,072,933		
 With security holder approval under rule 7.1 or rule 7.4 			
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
"C"	29,447,189		
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1	B"] to calculate remaining		
"A" x 0.15	33,866,057		
Note: number must be same as shown in Step 2			
Subtract "C"	29,447,189		
Note: number must be same as shown in Step 3			
Total ["A" x 0.15] – "C"	4,418,868		
	[Note: this is the remaining placement capacity under rule 7.1]		

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A" Note: number must be same as shown in Step 1 of Part 1, Less Institutional Placement	166,214,606		
Step 2: Calculate 10% of "A"			
"D"	0.10 Note: this value cannot be changed		
Multiply "A" by 0.10	16,621,461		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
 Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	16,621,461 - Institutional Placement		
"E"	16,621,461		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	16,621,461	
Subtract "E" Note: number must be same as shown in Step 3	16,621,461	
<i>Total</i> ["A" x 0.10] – "E"	Nil Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.